Coating member and method for manufacturing coating member

A polysiloxane-based coating member with a biguanide compound layer addresses adhesion and longevity issues, providing broad-spectrum pathogen resistance and sustained efficacy.

WO2026235175A1PCT designated stage Publication Date: 2026-11-12
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/017523
Authority / Receiving Office
WO · WO
Patent Type
Applications
Priority Date
2025-05-08
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing coatings with antibacterial, antifungal, or antiviral properties face challenges such as low adhesion to substrates, difficulty in uniform application, high cost for large surfaces, and short-lasting effects due to leaching of water-soluble biguanide compounds.

Method used

A coating member comprising a base material with a polysiloxane-based binder layer and a biguanide compound layer, where the two are mixed in the thickness direction, using a two-component composition that includes polysiloxane, silicon-containing compounds, fused silica, and a curing agent, allowing for high adhesion and long-lasting effects.

Benefits of technology

The coating exhibits excellent antibacterial, antifungal, and antiviral properties against a wide range of pathogens, including drug-resistant bacteria and viruses, with high adhesion and sustained effectiveness on various substrates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2026017523_12112026_PF_FP_ABST
    Figure JP2026017523_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides: a method for manufacturing a coating member having excellent antibacterial, antifungal, or antiviral properties; and a coating member obtained thereby. This method for manufacturing a coating member comprises: applying, to a surface of a substrate, a binder composition containing a curing agent and a main agent of a two-component composition containing at least polysiloxane, and performing heating or drying treatment to make the binder composition have a semi-cured dry state; applying, onto the binder composition in the semi-cured dry state, a biguanide-based compound solution containing a biguanide-based compound; and further performing heating or drying treatment to form a binder layer containing a silicone resin, a biguanide-based compound layer on the binder layer, and a mixed region which is provided in the thickness direction between the binder layer and the biguanide-based compound layer, and in which the silicone resin and the biguanide-based compound are mixed.
Need to check novelty before this filing date? Find Prior Art

Description

Coating member and method for manufacturing the coating member

[0001] The present invention relates to a coating substrate having antibacterial, antifungal, or antiviral properties, and a method for producing the coating substrate.

[0002] In recent years, infectious diseases such as drug-resistant norovirus and the novel coronavirus have been rampant. Furthermore, in addition to viruses, droplet infections caused by bacteria and fungi are known to be transmitted through contact with contaminated objects. Therefore, removing pathogens from objects is desirable as a countermeasure against such infections.

[0003] Patent Document 1 discloses a functional member in which cracks are formed in an inorganic binder cured layer containing a functional component having antibacterial or antiviral effects, which is formed on a resin substrate. Patent Document 2 describes imparting antibacterial or antiviral effects to a paint and forming and curing a film-like composition containing an organic antiviral agent such as chlorhexidine gluconate. Patent Document 3 discloses a technique for coating the surface of a substrate with a surfactant by irradiation with ultraviolet light, and it is stated that the surfactant is an analog having a biguanide structure such as chlorhexidine.

[0004] Japanese Patent Publication No. 2020-40267, Japanese Patent Publication No. 2023-33108, Japanese Patent Publication No. 2026-07323

[0005] According to the present invention, a method for manufacturing a coating member having excellent antibacterial, antifungal, or antiviral properties, and a coating member obtained thereby can be provided.

[0006] [1] A coating member comprising a base material, a binder layer provided on the base material, and a biguanide-based compound layer containing a biguanide-based compound covering over the binder layer, wherein the binder layer is in a cured and dried state of a binder composition containing polysiloxane, and a mixed region in which the polysiloxane and the biguanide-based compound are mixed is formed between the binder layer and the biguanide-based compound layer in the thickness direction of the binder layer.

[0007] [2] The polysiloxane is represented by General Formula (1): (wherein R 1 and R 2 each independently represent a hydrogen atom, a C 1 to C 3 alkyl group or a C 1 to C 3 alkoxy group. m1 and n1 are each independently an integer of 1 to 100, and m1+n1=10 to 100. Both terminals of the main chain may each independently be bonded to a hydrogen atom or a C 1 to C 3 alkyl group.) a silicone resin represented by: General Formula (2): (wherein p is an integer of 250 to 400. Both terminals of the main chain may each independently be bonded to a hydrogen atom or a C 1 to C 3 alkyl group.) polydimethylsiloxane represented by: and General Formula (3): (wherein R 3 and R 4 each independently represent a hydrogen atom, a C 1 to C 3 alkyl group or a C 1 to C 3 alkoxy group. m2 and n2 are each independently an integer of 1 to 10, and m2+n2=1 to 10. Both terminals of the main chain may each independently be bonded to a hydrogen atom or a C 1 to C 3 alkyl group.) one type selected from silicone resins represented by, or any combination thereof, the coating member according to [1].

[0008] [3] The coating member according to [1] or [2], wherein the biguanide compound is chlorhexidine, oranexidine, or polyhexamethylene biguanide, and is in the form of a free base that does not contain an acid-derived anion.

[0009] [4] The coating member according to any one of [1] to [3], wherein the base material is selected from metal, ceramics, glass, plastic, concrete, stone, wood, woven fabric, nonwoven fabric, or Japanese paper.

[0010] [5] A precursor for a coating member, comprising a substrate, a binder composition provided on the substrate, and a biguanide compound layer containing a biguanide compound covering the binder composition, wherein the binder layer is in a semi-cured and dried state of a binder composition containing polysiloxane.

[0011] [6] A method for manufacturing a coated member, comprising: applying a binder composition containing a main component and a curing agent of a two-component composition containing at least polysiloxane to the surface of a substrate; heating or drying the binder composition to a semi-cured state; applying a biguanide compound solution containing a free base of a biguanide compound on the semi-cured binder composition; and further heating or drying the binder composition to form a cured binder layer containing polysiloxane, a biguanide compound layer on the binder layer, and a mixed region between the binder layer and the biguanide compound layer in the thickness direction in which the polysiloxane and the biguanide compound are mixed.

[0012] [7] The solid content consists of the following components: (A) 40 to 95% by weight, preferably 60 to 90% by weight, more preferably 70 to 90% by weight of a polysiloxane compound, wherein the polysiloxane compound is a silicone resin represented by general formula (1); polydimethylsiloxane represented by general formula (2); or a silicone resin represented by general formula (3); or a combination thereof; (B) 1 to 20% by weight, preferably 1 to 10% by weight, more preferably 2 to 5% by weight of a silicon-containing compound, wherein the silicon-containing compound is selected from tetraalkyl orthosilicate (also known as "tetraalkoxysilane"; TEOS), silica, a mixture of TEOS and silica, vinyltrimethylsilane; (C) 0.5 to 10% by weight, preferably 1 to 10% by weight, more preferably 2 to 5% by weight of fused silica; and (D) 0.6% to 1.2% by weight of a curing agent or (G) 0.5 to 10% by weight, preferably 0.5 to 5% by weight, more preferably 0.5 to 3% by weight of an organometallic compound, wherein the organometallic compound may include titanium diisopropoxybis(ethyl acetate), tetrakis(2-ethylhexyl) or a combination thereof, as described in [6].

[0013] [8] The manufacturing method according to [7], wherein the entire binder composition may further contain the following components: (E) water; an organic acid selected from formic acid, acetic acid, citric acid, malic acid, lactic acid, succinic acid, tartaric acid and fumaric acid; or a catalyst selected from an inorganic acid selected from hydrochloric acid, nitric acid and sulfuric acid.

[0014] [9] The manufacturing method according to [7] or [8], which may further contain, with respect to the entire binder composition, the following component: (F) 1% to 25.0% by weight, preferably 3 to 20% by weight, more preferably 5 to 20% by weight, a solvent selected from methyl alcohol, ethyl alcohol, isopropyl alcohol (IPA), texanol (2,2,4-trimethylpentane-1,3-diol monoisobutyrate), plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, butanol, butylcarbitol acetate (BCA).

[0015]

[10] The method for producing a product according to any one of [6] to [9], wherein the biguanide compound is chlorhexidine, oranexidine, or polyhexamethylene biguanide, and is in the form of a free base that does not contain an acid-derived anion.

[0016]

[11] The method for producing the biguanide compound solution according to any one of [6] to

[10] , wherein the biguanide compound solution comprises a solvent selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, diisopropyl adipate, plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, or a combination thereof.

[0017]

[12] The manufacturing method according to any one of [6] to

[11] , wherein the content of the biguanide compound in the biguanide compound solution is 0.5% by weight or more and 65% by weight or less, preferably 5% by weight or more and 60% by weight or less, more preferably 10% by weight or more and 50% by weight or less.

[0018]

[13] The manufacturing method according to any one of [6] to

[12] , wherein the main component of the two-component composition comprises a silicon-containing compound and fused silica.

[0019]

[14] The manufacturing method according to

[13] , wherein the main component of the two-component composition further comprises an organometallic compound.

[0020]

[15] A biguanide compound solution comprising a biguanide compound and a solvent selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, diisopropyl adipate, 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol of plant origin, 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol of petroleum origin, or a combination thereof, wherein the biguanide compound is chlorhexidine, oranexidine or polyhexamethylene biguanide and is in the form of a free base that does not contain anions of acid origin.

[0021]

[16] General formula (1): (In the formula, R 1 and R 2 Each of these is independently a hydrogen atom, C 1 ~C 3 alkyl group or C 1 ~C 3 It is an alkoxy group. m1 and n1 are each an integer from 1 to 100, and m1 + n1 = 10 to 100. Both ends of the main chain are independently hydrogen atoms or C 1 ~C 3 A silicone resin represented by the following formula may have an alkyl group bonded to it: General formula (2): (In the formula, p is an integer between 250 and 400. Both ends of the main chain are independently hydrogen atoms or C 1 ~C 3 Polydimethylsiloxane represented by (which may have an alkyl group attached); and general formula (3): (In the formula, R 3 and R 4 These are, independently, hydrogen atoms and C 1 ~C 3 alkyl group or C 1 ~C 3It is an alkoxy group. m2 and n2 are each an integer from 1 to 10, and m2 + n2 = 1 to 10. Both ends of the main chain are independently a hydrogen atom or C 1 ~C 3 The biguanide compound solution according to

[15] further comprises a polysiloxane which is one selected from silicone resins represented by (which may have alkyl groups bonded to it) or any combination thereof.

[0022] According to the present invention, a method for manufacturing a coating member having excellent antibacterial, antifungal, or antiviral properties, and a coating member obtained thereby can be provided.

[0023] This is a schematic diagram illustrating a method for manufacturing a coating member according to one embodiment of the present invention. This is a schematic diagram illustrating a method for manufacturing a coating member according to one embodiment of the present invention. This is a schematic diagram illustrating a method for manufacturing a coating member according to one embodiment of the present invention. This is an end view of a coating member according to one embodiment of the present invention. This is a surface SEM image of a coating member according to one embodiment of the present invention. This is a cross-sectional STEM image of a coating member according to one embodiment of the present invention. This is the EDX mapping analysis result corresponding to the cross-sectional STEM image of a coating member according to one embodiment of the present invention. This is the EDX mapping analysis result corresponding to the cross-sectional STEM image of a coating member according to one embodiment of the present invention. This is the EDX mapping analysis result corresponding to the cross-sectional STEM image of a coating member according to one embodiment of the present invention. This is the EDX mapping analysis result corresponding to the cross-sectional STEM image of a coating member according to one embodiment of the present invention. This is the result of an antibacterial test performed on a coating member according to one embodiment of the present invention. This is the result of an antibacterial test performed on a coating member according to one embodiment of the present invention. This is the result of an antibacterial test performed on a coating member according to one embodiment of the present invention. This is the result of an antibacterial test performed on a coating member according to one embodiment of the present invention.

[0024] Hereinafter, one embodiment of the present invention will be described in detail with reference to the drawings. The present invention is not limited to the following embodiments and can be implemented in various modifications within the scope of its spirit.

[0025] A coating member and a method for manufacturing the same according to one embodiment of the present invention will be described. The coating member according to one embodiment of the present invention has an antibacterial effect, an antifungal effect, or an antiviral effect. In this specification, "antibacterial effect" is a concept that encompasses bactericidal effect and bacteriostatic effect. That is, it is considered to have an "antibacterial effect" not only when it reduces the number of viable bacteria of a particular bacterium, but also when it is confirmed to suppress the growth rate of a particular bacterium. In this specification, "antifungal effect" is a concept that encompasses fungicidal effect and fungal growth inhibitory effect. That is, it is considered to have an "antifungal effect" not only when it reduces the number of viable fungi of a particular fungus, but also when it is confirmed to suppress the growth rate of a particular fungus. In this specification, "antiviral effect" is a concept that encompasses pathogenic virus inactivation effect and viral growth inhibitory effect. That is, it is considered to have an "antiviral effect" not only when it alters or destroys the particles of a particular virus themselves, thereby rendering them infective, but also when it is confirmed to inhibit the replication and proliferation process of a particular virus.

[0026] In droplet infections caused by bacteria, fungi, and viruses, contact transmission via hands that have touched contaminated objects is a known route of transmission. To combat such infections, removing pathogens from objects is desirable. Furthermore, hospital-acquired infections are a major battleground, and drug-resistant bacteria and fungi (which are unaffected by existing drugs) and constantly mutating mutant viruses have the potential to trigger the next pandemic. Therefore, there is a strong demand for coating materials that exhibit high efficacy against a wide range of pathogens without relying on specific drug mechanisms.

[0027] The coating member according to one embodiment of the present invention exhibits antibacterial effects not only against bacteria such as methicillin-sensitive Staphylococcus aureus, wild-type Pseudomonas aeruginosa, and Enterococcus faecalis, but also against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-moderately resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecalis, as well as against Pseudomonas aeruginosa quadruple knockout strains with low resistance to drugs. Furthermore, the coating member according to one embodiment of the present invention also exhibits antibacterial effects against drug-resistant bacteria such as carbapenem-resistant Enterobacteriaceae, penicillin-resistant Streptococcus pneumoniae, extended-spectrum beta-lactamase-producing bacteria, AmpC-producing bacteria, multidrug-resistant Pseudomonas aeruginosa, and drug-resistant Acinetobacter. The site of action of the biguanide compound is the bacterial cell membrane (lipid membrane). Therefore, the coating member according to one embodiment of the present invention similarly exhibits antibacterial effects against bacteria other than those exemplified above, as well as drug-resistant bacteria.

[0028] The coating member according to one embodiment of the present invention exhibits antifungal effects against, for example, Candida, Aspergillus, Cryptococcus, Pneumocystis, Trichosporon, Trichomycetes, Malassezia, Sporotrichus, Black Fungi, Malassezia, Fusarium, Trichothecium, Cepharosporium, Rhzioctonia, Ceratobasidium, Magnaporthe, Ophiostomia, Cryphonectria, Ustilago, Alternaria, Cladosporium, and Rhodotomorula. Furthermore, the coating member according to one embodiment of the present invention exhibits antifungal effects against Candida. The site of action of biguanide compounds is the cell membrane (lipid membrane) of fungi. Therefore, the coating member according to one embodiment of the present invention exhibits antifungal effects on fungi other than those exemplified above.

[0029] A coating member according to one embodiment of the present invention exhibits antiviral effects against enveloped viruses and non-enveloped viruses. The coating member according to one embodiment of the present invention shows high inactivation activity against enveloped viruses such as SARS coronavirus, influenza virus (not only human and avian, but also swine and horse, etc.), MERS coronavirus, Ebola virus, novel coronavirus, smallpox virus, hepatitis B virus, measles virus, and rabies virus. As for non-enveloped viruses, it shows high viral inactivation activity against, for example, Caliciviridae viruses, and higher viral inactivation activity against Vesivirus and / or Norovirus viruses. It shows particularly high viral inactivation activity against at least one virus selected from the group consisting of feline calicivirus, murine norovirus, and human norovirus. Furthermore, the coating member according to one embodiment of the present invention is not limited to the above-mentioned non-enveloped viruses, but also shows viral inactivation activity against rotavirus, poliovirus, and adenovirus, etc.

[0030] A method for manufacturing a coating member according to one embodiment of the present invention, and in the coating member obtained thereby, a free base of a biguanide compound such as chlorhexidine, oranexidine, or polyhexamethylene biguanide is used as a substance that exhibits an antibacterial effect, an antifungal effect, or an antiviral effect.

[0031] [Chlorhexidine] In this specification, etc., chlorhexidine (molecular formula: C 22 H 30 Cl 2 N 10 The free base of chlorhexidine has a molecular weight of 505.4, a solubility in water at 20°C of approximately 80 mg / 100 mL (0.08 w / v%), and a length of 2.5 nm to 3.5 nm. Free chlorhexidine has low solubility in water. The chemical formula of free chlorhexidine is shown below as an example.

[0032] In this specification, when simply referred to as chlorhexidine, it means chlorhexidine (molecular formula: C22 H 30 Cl 2 N 10 This refers to the free base of chlorhexidine. "Free chlorhexidine base" means the form of a base in which the chlorhexidine molecule has not reacted with an acid to form a salt. In other words, it is a molecular state that is not bound to an anion, and is chemically represented as 1,1'-hexamethylenebis[5-(4-chlorophenyl)biguanide].

[0033] This form corresponds to compound CAS number 55-56-1, has low solubility in water (approximately 80 mg / 100 mL (0.08 w / v%), 20°C), and is relatively hydrophobic. Free bases typically behave differently from salts (e.g., chlorhexidine digluconate and hydrochloride) in terms of stability and solubility.

[0034] On the other hand, "chlorhexidine salts" refer to compounds formed when chlorhexidine reacts with an acid to form a salt, such as chlorhexidine digluconate and chlorhexidine hydrochloride. Commercially available "chlorhexidine-containing products" in medical, dental, skincare, and animal products are conventionally labeled as "containing chlorhexidine," but in reality, water-soluble "chlorhexidine salts" are used as the raw material.

[0035] [Oranexidine] In this specification, etc., oranexidine (molecular formula: C 17 H 27 Cl 2 N 5 The free base of ) has a molecular weight of 372.3, a solubility in water at 20°C of approximately 50 mg / 100 mL (0.05 w / v%), and a length of 3.0 nm to 4.0 nm. Oranexidine free base has low solubility in water. The chemical formula of oranexidine free base is shown below as an example.

[0036] In this specification, when simply referred to as olanexidine, it means olanexidine (molecular formula: C 17 H 27 Cl 2 N 5This refers to the free base of olanexidine. "Oranexidine free base" means the form of the base in which the olanexidine molecule has not reacted with an acid to form a salt. In other words, it is a molecular state that is not bound to an anion, and is chemically represented as 1-(3,4-dichlorobenzoyl)-5-octylbiguanide.

[0037] This form corresponds to compound CAS number 146510-36-3, has low solubility in water (approximately 50 mg / 100 mL (0.05 w / v%), 20°C), and is relatively hydrophobic. Free bases typically behave differently in terms of stability and solubility compared to salts (e.g., oranexidine digluconate or hydrochloride).

[0038] On the other hand, "olanexidine salts" refer to compounds formed when olanexidine reacts with an acid to form a salt, such as olanexidine digluconate and olanexidine hydrochloride. Commercially available "olanexidine-containing products" in medical, dental, skincare, and animal products are conventionally labeled as "containing olanexidine," but in reality, water-soluble "olanexidine salts" are used as the raw material.

[0039] [Polyhexamethylene biguanide] In this specification, etc., polyhexamethylene biguanide (molecular formula: (C) 8 H 17 N 5 )n , The free base of n=1-40 has a molecular weight of 183.2 × n, solubility in water at 20°C is approximately mg / 100 mL (w / v%), and length is nm to nm. Polyhexamethylene biguanide free base has low solubility in water. The chemical formula of polyhexamethylene biguanide free base is shown below as an example.

[0040] In this specification, when simply referred to as polyhexamethylene biguanide, it means polyhexamethylene biguanide (molecular formula: (C) 8 H 17 N 5 )n ,This refers to the free base of n=1-40. "Polyhexamethylene biguanide free base" means a base form in which the polyhexamethylene biguanide molecule has not reacted with an acid to form a salt. In other words, it is a molecular state that is not bound to an anion, and is chemically represented as polyhexamethylene biguanide.

[0041] This form is the compound corresponding to CAS number - -, has low solubility in water (approximately mg / 100 mL (w / v%), 20°C), and is relatively hydrophobic. Free bases generally behave differently in terms of stability and solubility compared to salts (e.g., polyhexamethylene biguanide gluconates and hydrochlorides).

[0042] On the other hand, "polyhexamethylene biguanide salts" refer to compounds formed when polyhexamethylene biguanide reacts with an acid to form a salt. Examples include polyhexamethylene biguanide gluconate and polyhexamethylene biguanide hydrochloride. Commercially available "polyhexamethylene biguanide-containing products" in medical, dental, skincare, and animal products are conventionally labeled as "containing polyhexamethylene biguanide," but in reality, water-soluble "polyhexamethylene biguanide salts" are used as raw materials.

[0043] When imparting antibacterial, antifungal, or antiviral effects to a substrate, one might consider applying a biguanide compound solution, obtained by dissolving a biguanide compound in an organic solvent such as ethyl acetate or texanol, to the substrate. However, it is difficult to apply the biguanide compound solution directly, uniformly, and with high adhesion to the substrate. Therefore, when applying a biguanide compound solution to the surface of a substrate, for example, applying the biguanide compound solution to a porous membrane allows the biguanide compound to be supported inside the pores, thereby exhibiting antibacterial, antifungal, or antiviral effects.

[0044] However, when attempting to apply a biguanide compound solution to a large surface area of ​​a large structure, such as a wall, forming a porous film on the wall increases costs and makes on-site application difficult. Conventionally, paints with antibacterial, antifungal, or antiviral effects that can be applied on-site have been made by mixing in metals such as silver, but even if the effect is long-lasting, the immediate effect is suppressed, which is a problem.

[0045] Furthermore, free bases of biguanide compounds have low solubility in water and are therefore usually difficult to dissolve in paints. For this reason, when dissolving biguanide compounds in paints, biguanide compound glucons, which have high solubility in water, are often used. However, although biguanide compound glucons provide an immediate effect, their high solubility in water leads to leaching, making it difficult to achieve sustained antibacterial, antifungal, or antiviral effects.

[0046] Therefore, one of the objectives of this embodiment is to provide a coating member that exhibits high adhesion regardless of the surface condition of the substrate. In other words, one of the objectives is to provide a coating member that exhibits high immediate and long-lasting antibacterial, antifungal, or antiviral effects.

[0047] <1. Method for Manufacturing the Coating Member> Next, a method for manufacturing the coating member 100 according to one embodiment of the present invention will be described with reference to Figures 1 to 4.

[0048] <2. Binder Composition> The binder composition comprises all or part of (A) polysiloxane, (B) silicon-containing compound, (C) fused silica, and (D) curing agent.

[0049] (A) Polysiloxanes Polysiloxanes are added to impart viscosity properties to the binder composition that allow for screen printing. Examples of polysiloxanes applicable to one embodiment of the present invention include compounds represented by general formulas (1) to (3).

[0050] General formula (1): (In the formula, R 1 and R 2Each of these is independently a hydrogen atom, C 1 ~C 3 alkyl group or C 1 ~C 3 It is an alkoxy group. m1 and n1 are each an integer from 1 to 100, and m1 + n1 = 10 to 100. Both ends of the main chain are independently hydrogen atoms or C 1 ~C 3 A silicone resin represented by (which may have alkyl groups bonded to it).

[0051] General formula (2): (In the formula, p is an integer between 250 and 400. Both ends of the main chain are independently hydrogen atoms or C 1 ~C 3 A polydimethylsiloxane represented by (which may have an alkyl group attached).

[0052] General formula (3): (In the formula, R 3 and R 4 These are, independently, hydrogen atoms and C 1 ~C 3 alkyl group or C 1 ~C 3 It is an alkoxy group. m2 and n2 are each an integer from 1 to 10, and m2 + n2 = 1 to 10. Both ends of the main chain are independently a hydrogen atom or C 1 ~C 3 A silicone resin represented by (which may have alkyl groups bonded to it).

[0053] An example of a silicone resin represented by general formula (1) is SILRES® MK, a silicone resin manufactured by Asahi Kasei Wacker Silicone Co., Ltd., whose cured product is relatively hard on its own. An example of a polydimethylsiloxane represented by general formula (2) is polydimethyl silicate (PDMS) "EL0039G" manufactured by Gootech Co., Ltd. (distributor: Juke Co., Ltd.), whose cured product is relatively soft on its own. An example of a silicone resin represented by general formula (3) is SILRES® MSE100, a liquid silicone resin manufactured by Asahi Kasei Wacker Silicone Co., Ltd.

[0054] Polysiloxanes represented by general formulas (1) to (3) differ in the number of silicate units (or molecular weight), and each exhibits a different hardness when cured individually. Depending on the substrate and environment to which the binder composition is applied, they can be used individually or in combination, taking into consideration the desired viscosity characteristics, crack resistance, and adhesion to the substrate.

[0055] (B) Silicon-containing compounds Silicon-containing compounds act as nodes when crosslinking polysiloxanes to form a three-dimensional network. Examples of silicon-containing compounds include tetraalkyl orthosilicates such as tetraalkyl orthosilicate (also called "tetraethoxysilane"; TEOS), silane compounds such as triethylsilane, silica, mixtures of TEOS and silica, vinyltrimethylsilane known as a silane coupling agent, or combinations thereof. Silane compounds such as TEOS can be hydrolyzed to nano-sized silica in the presence of water. Alternatively, nano-sized silica can be used directly. Furthermore, nano-sized silica can be produced from silane compounds such as TEOS using the sol-gel method.

[0056] Examples of silane compounds include Wacker® SILICATE TES 28 and Wacker® SILICATE TES 40 WN. Wacker® SILICATE TES 28 is a monomer-type ethyl silicate, and undergoes a hydrolysis reaction to produce approximately 28% by weight of SiO₂. 2 It is a low-viscosity, colorless liquid containing [unclear]. It undergoes rapid Si-O- conversion via hydrolysis. Wacker® SILICATE TES 40 WN is an ethyl silicate polymer, and upon complete hydrolysis, it yields approximately 41% by weight of SiO [unclear]. 2 It is a low-viscosity liquid that produces [a certain compound]. It undergoes slow Si-O- conversion via hydrolysis and readily binds to polydialkyl silicates such as PDMS.

[0057] In the present invention, (A) polysiloxane can be mixed with a portion of (B) a silicon-containing compound to form a two-component mixture, or this mixture can be used as a reaction product obtained by further reacting it. The reaction product of (A) polysiloxane and (B) silicon-containing compound can be obtained, for example, by mixing PDMS with a silane compound such as TEOS and heating it together with a catalyst. For example, there is a product such as the silicone resin compound "EL0039G" manufactured by Gootech Co., Ltd. (distributor: Juke Co., Ltd.). Such a reaction product of (A) polysiloxane and (B) silicon-containing compound (for example, the above-mentioned silicone resin compound) forms a three-dimensional network with nano-sized silica as nodes.

[0058] (C) Fused Silica Fused silica is a high-surface-area aggregate with a chain structure of spherical particles, and silanol groups are present on its surface, which are involved in network formation with polysilanol compounds. An example of fused silica is AEROSIL® R805 manufactured by Nippon Aerosil Co., Ltd.

[0059] (D) Curing agent The curing agent promotes the hydrolysis reaction of polysilanol compounds and silane compounds. Compounds known as curing agents include C 6 ~C 25 Examples of metal salts of carboxylic acids, such as hexyl acid, octic acid, 2-ethylhexanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, ricinoleic acid, and behenic acid, with Co, Mn, Zn, Sn, Zr, Fe, Ni, Ca, K, and Li, preferably Zr, Sn, and Zn. More preferably, zirconium octoate, for example, Nikka Octix® Zirconium [Zirconium Octoate] manufactured by Nippon Chemical Industries, Ltd. On the other hand, if Ti is used as the metal, the reaction is too fast and inconvenient to use in the present invention.

[0060] (E) Catalyst A catalyst may be added to lubricate the hydrolysis of the polysilanol compound. The catalyst may also be added depending on the type of substrate to be coated. When the silanol groups of the polysilanol compound or silane compound undergo hydrolysis and dehydration condensation, water may be generated and foam may occur. In order to substantially suppress the generation of foam while allowing hydrolysis to proceed, a very small amount of water and acid is added in proportion to the amount of the polysilanol compound. As the acid, organic acids such as formic acid, acetic acid, citric acid, malic acid, lactic acid, succinic acid, tartaric acid, and fumaric acid, or inorganic acids such as hydrochloric acid, nitric acid, and sulfuric acid can be used. Organic acids are preferred over inorganic acids because they result in a milder reaction, and acetic acid is more preferred.

[0061] (F) Solvent The solvent is an optional component for adjusting the viscosity of the binder composition. Examples of solvents include methyl alcohol, ethyl alcohol, isopropyl alcohol (IPA), texanol (2,2,4-trimethylpentane-1,3-diol monoisobutyrate), plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, butanol, and butylcarbitol acetate (BCA). For example, a plant-derived 1,2-propanediol is propylene glycol "Radianol®" manufactured by Oleon GmbH in Belgium, and a plant-derived 1,3-propanediol is 1,3-propanediol "Susterra®" manufactured by ConvationBio PDO GmbH.

[0062] (G) Organometallic compounds Organometallic compounds are added to lubricate the dehydration condensation reaction between polysilanol compounds. Examples of organometallic compounds that can be used in the present invention include Orgatics TC-750 (titanium diisopropoxybis(ethylacetoacetate) [Ti(Oi-C3H7)2(C6H9O3)2]) manufactured by Matsumoto Fine Chemical Co., Ltd., and tetrakis(2-ethylhexyl) orthotitanate.

[0063] The additive (H) binder composition is useful as a coating, and may contain various additives that are usually included in similar compositions. Examples of additives include, but are not limited to, any one selected from pigments, dyes, rust prevention measures, stainless steel metal powder, sulfidation resistance materials, luminous agents, fluorescent agents, photocatalysts, antibacterial ions, thermochromic substances, X-ray and radiation shielding materials, electromagnetic wave shielding materials, insulators, heat insulating materials, sound absorbing materials, moisture absorbing materials, and visible light / UV light reflecting materials, or combinations thereof.

[0064] Examples of the rust prevention measures and stainless steel metal powder include stainless steel flakes. As the sulfidation resistance material, in addition to stainless steel flake metal powder, Al 2 O 3 , TiO 2 , ZrO 2 , and the like may be added. These additive materials provide improved interfacial adhesion, blocking of diffusion paths (labyrinth effect, gas barrier properties), suppression of sulfidation reactions, and reduction of "initial nuclei" for sulfide formation (active site blocking). Examples of the luminous material include strontium aluminate activated with dysprosium and europium (Sr 4 Al 14 O 26 : Eu, Dy). Examples of the photocatalyst include TiO 2 , WO 3 (visible light responsive). Examples of antibacterial ions include silver ions and copper ions. Examples of the thermochromic substance include vanadium dioxide (VO 2 ). Examples of the X-ray and radiation shielding material include tungsten metal powder. Examples of the electromagnetic wave shielding material include ferrite. Examples of the insulator include alumina (Al 2 O 3 ), aluminum nitride (AlN), Low-K glass, and boron nitride (BN). Examples of the moisture absorbing material include zeolite powder and diatomaceous earth powder. Examples of the heat insulating material include perlite powder, hollow glass beads, silica aerogel powder, and expanded vermiculite powder. Examples of the sound absorbing material include cellulose powder, melamine resin foam powder, polyurethane foam powder, and porous silica powder. By having a porous structure or a hollow structure, these materials can impart heat insulating properties or sound absorbing properties. Further, as the visible light / UV light reflecting material, Al2 O 3 , TiO 2 , Zn, ZnO, SiO 2 , CeO 2 , mica, titanium oxide-coated mica, organic ultraviolet absorbers (such as benzotriazole-based ones), and the like. These materials improve the weather resistance and base material protection performance of the coating by reflecting, scattering or absorbing ultraviolet rays.

[0065] The binder composition according to one embodiment of the present invention includes a heat-curable binder composition and a room temperature-curable binder composition. The heat-curable binder composition and the room temperature-curable binder composition may be selected according to the material of the substrate to be coated, the heat-resistant temperature of the base material, the coating location (outdoor or indoor), and the presence or absence of heating equipment.

[0066] <3. Method for preparing heat-curable binder composition> First, the method for preparing the heat-curable binder composition will be described. In the present embodiment, a two-component binder composition is used as the binder composition.

[0067] The two-component binder composition at least comprises (A) polysiloxane, (B) silicon-containing compound, (C) fused silica, (D) curing agent, (E) catalyst, and (F) solvent.

[0068] As (A) polysiloxane, a silicone resin represented by general formula (1) and polydimethylsiloxane represented by general formula (2) are used. The content of the silicone resin represented by general formula (1) is 45.0 wt% to 85.0 wt% relative to the total amount of the binder composition. In addition, the content of the polydimethylsiloxane represented by general formula (2) is 7.0 wt% to 24.0 wt% relative to the total amount of the binder composition.

[0069] (B) The content of silicon-containing compounds is 2.2% to 8.5% by weight of the total amount of the binder composition. (C) The content of fused silica is 0.3% to 3.0% by weight of the total amount of the binder composition. (D) The content of curing agent is 1.0% to 5.0% by weight of the total amount of the binder composition. (F) The content of solvent is 20.0% to 25.0% by weight of the total amount of the binder composition. Also, (E) the content of catalyst may be 0.6% to 1.2% by weight of the total amount of the binder composition.

[0070] As STEP 1 of the method for preparing a heat-curing binder composition, the main component of the two-component composition is prepared. First, polydimethylsiloxane represented by general formula (2) is mixed as the polysiloxane, TES reagent and TEOS reagent are mixed as silicon-containing compounds, and fused silica is mixed. To the mixture obtained by mixing these, acetic acid is added as a catalyst, and IPA and Texanol are added as solvents, and the mixture is stirred. For example, stirring is performed at 80°C using a tornado mixer (600 rpm) for 65 minutes.

[0071] In STEP 2, to the composition prepared in STEP 1, for example, a silicone resin represented by general formula (1) as a polysiloxane, and IPA and Texanol as solvents are added and stirred. The stirring is performed, for example, at 80°C using a tornado mixer (600 rpm) for 65 minutes. This allows the main component of the two-component composition to be prepared.

[0072] A binder composition can be prepared by adding zirconium octylate as a curing agent to the main component of a two-component composition immediately before applying the binder composition to the substrate. When the viscosity of the binder composition is measured using a B-type viscometer at a temperature of 25°C, the viscosity of the binder composition is, for example, 15,000 mPa·s to 30,000 mPa·s.

[0073] The weight ratio of the main component to the hardener in a two-component composition is, for example, main component:hardener = 100:3 to 100:10.

[0074] <4. Method for preparing a biguanide compound solution> Next, prepare a biguanide compound solution. The biguanide compound solution contains an organic solvent. Here, chlorhexidine will be used as an example of a biguanide compound.

[0075] In this specification, the state in which chlorhexidine is dissolved in an organic solvent includes both a state in which chlorhexidine is completely dissolved and a state in which it is partially or completely insoluble but suspended at a level that does not pose a practical problem. "A suspension at a level that does not pose a practical problem" refers to a suspension state of chlorhexidine solution that increases the viscosity of the chlorhexidine solution and is suitable for screen printing or spray coating.

[0076] Examples of organic solvents capable of dissolving chlorhexidine include methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, 1,2-propanediol, 1,3-propanediol, 1,2,3-propanetriol, vinyl acetate, ethyl acetate, and methyl ethyl ketone. For example, when applying a chlorhexidine solution by screen printing, a higher viscosity makes application easier, so it is preferable to adjust the viscosity with an organic solvent. The chlorhexidine solution may contain a solvent selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, diisopropyl adipate (DIPA, also known as diisopropyl adipate), plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, or combinations thereof. Texanol, and in particular isopropyl adipate, plant-derived 1,2-propanediol or 1,3-propanediol, and 1,2,3-propanetriol, are highly safe, can increase the viscosity of chlorhexidine solutions, and are suitable for screen printing or spray coating. This embodiment describes the case in which texanol is used as an organic solvent.

[0077] Chlorhexidine is added to Texanol and stirred. Stirring is performed, for example, at 80°C using a tornado mixer (600 rpm) for 65 minutes. The viscosity of the chlorhexidine solution should be set according to the method of application of the chlorhexidine solution. When measured using a B-type viscometer at a temperature of 25°C, the viscosity of the chlorhexidine solution should be, for example, 3200 mPa·s to 8500 mPa·s.

[0078] The chlorhexidine content of the chlorhexidine solution should be 0.5% to 65% by weight relative to the total volume, and the organic solvent content should also be 0.5% to 65% by weight. Furthermore, when using methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, diisopropyl adipate, 1,2-propanediol, 1,3-propanediol, or 1,2,3-propanetriol, or a mixture thereof, if the chlorhexidine content is 0.5% to 65% by weight, 100% or partial dissolution will occur, resulting in a suspension state at a level that poses no practical problems.

[0079] <5. Formation of Heat-Curing Coating Member> Next, the formation of the coating member will be explained with reference to Figures 1 to 4. As shown in Figure 1, the binder composition 114 described above is applied onto the substrate 102.

[0080] Methods for applying the binder composition 114 include screen printing, flexographic printing, and gravure printing. The heat-curing binder composition 114 should be applied to a thickness of 4 μm to 70 μm using the above-described application method.

[0081] Next, as shown in Figure 2, the binder composition 114 applied to the substrate is subjected to heat treatment. The heat treatment is carried out using a hot air drying oven, a hot plate, or infrared irradiation at 100°C to 130°C for 15 to 30 minutes. The heat treatment initiates polymerization of the polysiloxane contained in the binder composition 114, thereby promoting hardening. The solvent contained in the binder composition 114 is also evaporated to form a semi-cured binder composition 114A. The layer of cured binder composition 114 is also called the binder layer 104. At this time, the thickness of the semi-cured binder composition 114A layer is 3 μm to 50 μm.

[0082] Next, as shown in Figure 3, the chlorhexidine solution 116 is applied to the semi-cured binder composition 114A. Examples of application methods include screen printing, flexographic printing, gravure printing, and spray coating. The chlorhexidine solution 116 should be applied to a thickness of 1 μm to 120 μm using the above application method.

[0083] Next, the semi-cured binder composition 114A coated with chlorhexidine solution 116 is subjected to further heat treatment. The heat treatment is carried out using a hot air drying oven, a hot plate, or infrared irradiation, for example, for 180 to 240 minutes at 150°C, or for 90 to 120°C at 180°C. This heat treatment further evaporates the solvent contained in the binder composition 114, promoting curing and forming the binder layer 104. The binder layer 104 can be described as the state in which the binder composition 114 has cured and dried and the solvent has been removed. Furthermore, by evaporating the solvent contained in the chlorhexidine solution 116, a chlorhexidine layer 106 can be formed on top of the binder layer 104. That is, the solvent contained in the binder composition 114A and the chlorhexidine solution 116 evaporates to form the binder layer 104, and at the same time, the surface of the chlorhexidine layer 106 dries to the point where it does not feel fluid to the touch.

[0084] Furthermore, during the heat treatment, the solvent in the semi-cured binder composition 114A evaporates and curing progresses, and at the same time, as the solvent contained in the chlorhexidine solution 116 evaporates, the interface between the semi-cured binder composition 114A and the chlorhexidine solution 116 mixes. As a result, a mixed region 108 is formed between the binder layer 104 and the chlorhexidine layer 106 in the thickness direction, where the silicone resin contained in the binder layer 104 and the chlorhexidine are mixed. The coated member 100 can be manufactured through the above process.

[0085] <6. Configuration of the coating member> Figure 4 is an end view of a coating member 100 according to one embodiment of the present invention. The coating member 100 is provided on a substrate 102 and has a binder layer 104 containing a silicone resin, a chlorhexidine layer 106 containing chlorhexidine covering the binder layer 104, and a mixed region 108 between the binder layer 104 and the chlorhexidine layer 106 in the thickness direction in which the silicone resin contained in the binder layer 104 and the chlorhexidine are mixed.

[0086] Examples of the base material 102 include metal, ceramics, glass, plastic, concrete, stone, wood, woven fabric, nonwoven fabric, nonwoven protective clothing, or Japanese paper. The surface of the base material 102 may be lipophilic or hydrophilic. When using a heat-curing binder composition, the base material 102 should be a material with a heat resistance of 185°C or higher. For example, the base material 102 may be a metal such as aluminum, copper, or steel plate, ceramics, glass, plastic, concrete, or stone. When using a room-temperature curing binder composition, the base material 102 may be a material with a heat resistance of less than 185°C. For example, the base material 102 may be a metal such as aluminum, copper, or steel plate, ceramics, glass, plastic with a heat resistance of 185°C or higher, concrete, or stone, as well as plastic with a heat resistance of less than 185°C, wood, woven fabric, nonwoven fabric, nonwoven protective clothing, or paper or Japanese paper.

[0087] The binder layer 104 is formed by curing a binder composition containing a main component and a curing agent of a two-component composition containing at least the polysiloxane described above. The thickness of the binder layer 104 is 3 μm to 50 μm. The thickness of the binder layer 104 can be measured, for example, with a microgauge capable of measuring to a minimum of 1 μm. The binder layer 104 can also be observed from images obtained by EDX mapping analysis of cross-sectional STEM images obtained by observing the cross-sectional STEM. Specifically, the region where neither nitrogen (N) nor chlorine (Cl) derived from chlorhexidine is detected (black area in the image obtained by EDX mapping analysis) is the region of the binder layer 104.

[0088] The chlorhexidine layer 106 contains chlorhexidine. Alternatively, the chlorhexidine layer 106 may be a layer consisting of chlorhexidine. The thickness of the chlorhexidine layer 106 after drying may be, for example, 0.5 μm or more and 60 μm or less, preferably 1 μm or more and 20 μm or less, and more preferably 5 μm or more and 20 μm or less. The thickness of the chlorhexidine layer 106 after drying can be measured, for example, by EDX mapping analysis of a cross-sectional STEM image obtained by observing the cross-sectional STEM. Specifically, the thickness of the chlorhexidine layer 106 is the region in which at least one of nitrogen (N) and chlorine (Cl) derived from chlorhexidine is detected (the bright portion in the image obtained by EDX mapping analysis).

[0089] The mixed region 108 is a region in the thickness direction of the binder layer 104 where the silicone resin and chlorhexidine are mixed. After drying, the mixed region 108 is provided with a thickness of 0.1 μm to 5 μm in the thickness direction. The thickness of the mixed region 108 can be measured, for example, by EDX mapping analysis of a cross-sectional STEM image obtained by observing the cross-sectional STEM. Specifically, the thickness of the mixed region 108 is the region in which at least one of nitrogen (N) and chlorine (Cl) derived from chlorhexidine is detected (in the image obtained by EDX mapping analysis, the part that is brighter than the binder layer 104 and darker than the chlorhexidine layer 106).

[0090] According to a method for manufacturing a coating member 100 according to one embodiment of the present invention, a chlorhexidine solution 116 is applied to a semi-cured binder composition 114A, and then a heat treatment is performed to form a chlorhexidine layer 106 on a cured binder layer 104. In addition, a mixed region 108 in which silicone resin and chlorhexidine are mixed is formed between the binder layer 104 and the chlorhexidine layer 106.

[0091] The binder layer 104 constituting the coating member 100 has high adhesion to the substrate 102. Furthermore, the binder layer 104 does not repel the chlorhexidine solution even if it is hydrophilic. Therefore, a chlorhexidine layer 106 can be uniformly formed on the substrate 102 via the binder layer 104. In addition, a mixed region 108 in which chlorhexidine is mixed can be formed in the binder layer 104, thereby improving the adhesion between the binder layer 104 and the chlorhexidine layer 106.

[0092] The binder composition 114 and the chlorhexidine solution 116 can be applied by methods such as screen printing. Therefore, the coating member 100 can be applied inexpensively on-site to large structures such as building materials, wall materials, and floor materials.

[0093] <7. Antibacterial effect of the coating material> Since the chlorhexidine layer 106 is exposed on the surface of the coating member 100, an immediate antibacterial effect is obtained. In addition, the chlorhexidine free base contained in the chlorhexidine layer 106 has low solubility in water and also low solubility in disinfectant ethanol, so its easy dissolution is suppressed. Therefore, the duration of the antibacterial effect of the coating member 100 can be improved.

[0094] If the surface of the coating member 100 is scraped or dirt adheres to the surface after a predetermined period of time has elapsed since using the coating member 100, the antibacterial effect may decrease. In this case, a chlorhexidine solution 116 may be applied to the surface of the coating member 100. When the applied chlorhexidine solution 116 dries, a chlorhexidine layer 106 of the coating member 100 can be laminated. This exposes chlorhexidine, which has a high antibacterial effect, and thus the antibacterial effect of the coating member 100 can be prolonged.

[0095] The mechanism by which chlorhexidine destroys bacteria when they adhere to the coating member 100 will be explained. Normally, bacteria are contained in droplets, which are primarily watery, produced by coughing or phlegm, and are dispersed in this liquid. When droplets containing bacteria adhere to the surface of the coating member 100, a small amount of chlorhexidine free base dissolves into the droplets. The dissolved chlorhexidine free base interacts with the bacteria, affecting the surface structure such as the cytoplasmic membrane and cell wall, as well as proteins within the bacterial body, thereby destroying and killing the bacteria. Chlorhexidine can also destroy drug-resistant bacteria, such as the methicillin-resistant Staphylococcus aureus and vancomycin-resistant Staphylococcus aureus mentioned above. Therefore, the coating member 100 with chlorhexidine exposed on its surface can suppress bacterial growth over a long period of time. However, it is possible that the antibacterial effect of chlorhexidine may decrease if bacteria undergo mutations in their surface structure or components. However, since significantly altering the surface structure or components of bacteria is detrimental to their survival, it is thought that drug-resistant strains to chlorhexidine are relatively unlikely to develop.

[0096] Chlorhexidine is aggressive against bacteria, but when leached by water, it may attack non-bacterial substances. For example, chlorhexidine gluconate has high solubility in water, so even if it is used in a chlorhexidine layer, if moisture adheres to the surface of the chlorhexidine layer, the chlorhexidine gluconate will leach out. If a person's finger comes into contact with the leached chlorhexidine gluconate and it comes into contact with mucous membranes or wounds via the finger, there is a risk of anaphylactic shock. In addition, the leaching of chlorhexidine gluconate has the problem of reduced duration of antibacterial effect.

[0097] In one embodiment of the present invention, the chlorhexidine layer uses chlorhexidine free base, which is poorly soluble in water and disinfectant ethanol, rather than the water-soluble chlorhexidine gluconate, which is the main commercially available product currently on the market. This makes it possible to suppress the leaching of chlorhexidine even if moisture adheres to the surface of the coating member 100. It also makes it possible to suppress the adhesion of chlorhexidine even if a person's finger touches the surface of the coating member 100. This improves safety. Furthermore, it is possible to improve the persistence of the antibacterial effect of the coating member 100.

[0098] In this embodiment, a case has been described in which a chlorhexidine solution 116 is applied to a semi-cured binder composition 114A, and the curing of the binder composition 114A and the drying of the chlorhexidine solution 116 are performed simultaneously. However, the embodiment of the present invention is not limited to this. It is also possible to apply a chlorhexidine solution 116 to a semi-cured and dried binder composition 114A and dry the chlorhexidine solution 116 at room temperature. As a result, the solvent of the chlorhexidine solution 116 evaporates, so that a chlorhexidine layer 106 can be formed on the semi-cured and dried binder composition 114A. Subsequently, the semi-cured and dried binder composition 114A is cured by heat treatment to form a binder layer 104.

[0099] <8. Method for preparing a room-temperature curing binder composition> Next, a method for preparing a room-temperature curing binder composition will be described. In this embodiment, a two-component binder composition is used as the binder composition. Room temperature refers to a temperature of 15°C to 30°C.

[0100] The two-component binder composition comprises at least (A) polysiloxane, (C) fused silica, (D) curing agent, (E) catalyst, and (F) solvent. The two-component binder composition may further contain (B) silicon-containing compound and (G) organometallic compound.

[0101] (A) As polysiloxane, a silicone resin represented by general formula (1), a polydimethylsiloxane represented by general formula (2), and a silicone resin represented by general formula (3) are used. The content of the silicone resin represented by general formula (1) is 15.0% to 70.0% by weight of the total amount of the binder composition. The content of the polydimethylsiloxane represented by general formula (2) is 2.0% to 8.0% by weight of the total amount of the binder composition. The content of the silicone resin represented by general formula (3) is 20.0% to 85.0% by weight of the total amount of the binder composition.

[0102] (C) The fused silica content is 0.3% to 3.0% by weight of the total amount of the binder composition. (D) The curing agent content is 1.0% to 5.0% by weight of the total amount of the binder composition. (F) The solvent content is 5.0% to 8.0% by weight of the total amount of the binder composition. Also, (B) the silicon-containing compound content may be 2.2% to 8.5% by weight of the total amount of the binder composition. (G) The organometallic compound content may be 0.5% to 3.0% by weight of the total amount of the binder composition.

[0103] As STEP 1 of the method for preparing a room-temperature curing binder composition, the main component of the two-component composition is prepared. First, IPA is added to a silicone resin represented by general formula (1) as the polysiloxane and stirred. The stirring is performed, for example, at 85°C using a tornado mixer (600 rpm) for 65 minutes.

[0104] In STEP 2, the composition prepared in STEP 1 is mixed with, for example, polydimethylsiloxane represented by general formula (2), a silicone resin represented by general formula (3), and fused silica as polysiloxanes. Furthermore, a silicon-containing compound and an organometallic compound are mixed in to promote room-temperature curing. The mixture obtained by mixing these is stirred. The stirring is performed, for example, at 85°C using a tornado mixer (600 rpm) for 65 minutes. This allows for the preparation of a two-component main component composition.

[0105] A binder composition can be prepared by adding zirconium octylate as a curing agent to the main component of a two-component composition immediately before applying the binder composition to the substrate. When the viscosity of the binder composition is measured using a B-type viscometer at a temperature of 25°C, the viscosity of the binder composition is, for example, 400 mPa·s to 10000 mPa·s.

[0106] The weight ratio of the main component to the hardener in a two-component composition is, for example, main component:hardener = 100:3 to 100:10.

[0107] <9. Formation of Room-Temperature Curing Coating Member> Next, the formation of the coating member will be explained with reference to Figures 1 to 4. As shown in Figure 1, the binder composition 114 described above is applied to the substrate 102.

[0108] Methods for applying the binder composition 114 include screen printing, flexographic printing, and gravure printing. The binder composition 114 should be applied to a thickness of 5 μm to 90 μm using the above-described application method.

[0109] Next, as shown in Figure 2, the binder composition 114 applied to the substrate is subjected to a drying treatment. Outdoors, the drying treatment is performed at ambient temperature for 30 to 360 minutes. Indoors, it is performed at 20°C to 30°C for 20 to 360 minutes. In the case of a room-temperature curing type binder composition 114, after applying the binder composition 114 to the substrate, polymerization of polysiloxane proceeds as the solvent evaporates at room temperature. By leaving the binder composition 114 applied to the substrate 102 at room temperature, a semi-cured binder composition 114A can be formed. If a hot air drying oven is used for the drying treatment, it may be dried at 30°C to 50°C for 10 to 20 minutes. At this time, the thickness of the semi-cured binder composition 114A will be 3 μm to 50 μm.

[0110] Next, as shown in Figure 3, the chlorhexidine solution 116 is applied to the semi-cured binder composition 114A. Examples of application methods include screen printing, flexographic printing, gravure printing, and spray coating. The chlorhexidine solution 116 should be applied to a thickness of 1 μm to 120 μm using the above application method.

[0111] Next, the semi-cured binder composition 114A coated with chlorhexidine solution 116 is subjected to further drying. Outdoors, the drying process is carried out at ambient temperature for 180 to 480 minutes. Indoors, the drying process is carried out at 20°C to 30°C for 180 to 480 minutes. This drying process further volatilizes the solvent contained in the binder composition 114, promoting curing and forming the binder layer 104. Additionally, by volatilizing the solvent contained in the chlorhexidine solution 116, a chlorhexidine layer 106 can be formed on top of the binder layer 104. Furthermore, during the drying process, as the solvent in the semi-cured binder composition 114 volatilizes and curing progresses, and as the solvent contained in the chlorhexidine solution 116 volatilizes, the interface between the semi-cured binder composition 114 and the chlorhexidine solution 116 mixes. As a result, a mixed region 108 is formed between the binder layer 104 and the chlorhexidine layer 106 in the thickness direction, where the binder layer 104 and chlorhexidine are mixed. When using a hot air drying oven for the drying process, drying may be performed at 30°C to 90°C for 30 to 360 minutes. The coated member 100 can be manufactured by the above process.

[0112] <10. Composition of the coating member> Even when a room-temperature curing binder composition 114 is used, the coating member 100 according to one embodiment of the present invention can be constructed. For details of the composition of the coating member 100, please refer to the explanation in Figure 4. The thickness of the binder layer 104 after drying is 3 μm or more and 50 μm or less, and the thickness of the chlorhexidine layer 106 after drying is 0.5 μm or more and 60 μm or less. The thickness of the mixed region 108 after drying is 0.1 μm or more and 5 μm or less.

[0113] <11. Method for preparing binder compositions for paints and coatings> Although methods for applying heat-curing and room-temperature curing binder compositions 114 by various printing methods have been described, the embodiment of the present invention is not limited thereto. For example, heat-curing and room-temperature curing binder compositions 114 can also be applied to paints and coatings.

[0114] The method for preparing the binder composition 114 for paint is generally the same as the method for preparing the binder composition for printing. When using heat-curing and room-temperature curing binder compositions as binder compositions for paint, the viscosity of the main component of the two-component composition can be adjusted to a predetermined viscosity using a solvent. Examples of solvents for adjusting viscosity include methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, 1,2-propanediol, 1,3-propanediol, 1,2,3-propanetriol, butanol, and butylcarbitol acetate (BCA).

[0115] The binder composition 114 can be prepared by adding titanium ethyl acetate as a curing agent to the main component of a two-component composition whose viscosity has been adjusted, immediately before applying the binder composition 114 to the substrate. Examples of titanium ethyl acetate include Matsumoto Fine Chemical Co., Ltd.'s metal soap (organometallic compound: MO) "OrganicsTC750".

[0116] When a heat-curing binder composition is used as a paint coating, the viscosity of the binder composition should be, for example, between 80,000 mPa·s and 120,000 mPa·s, when measured using a B-type viscometer at a temperature of 25°C. Similarly, when a room-temperature curing binder composition is used as a paint coating, the viscosity of the binder composition should be, for example, between 60,000 mPa·s and 100,000 mPa·s, when measured using a B-type viscometer at a temperature of 25°C.

[0117] The weight ratio of the main component to the curing agent in the two-component composition is, for example, main component:curing agent = 100:3 to 10. In this way, heat-curing or room-temperature curing binder compositions can be prepared.

[0118] Furthermore, when using heat-curing or room-temperature curing binder compositions as paint, the viscosity of the paint can be reduced by diluting the binder composition with a commonly used diluent (thinner) such as isopropyl alcohol, mineral spirits, or butyl acetate before use.

[0119] <12. Formation of Coating Members> The case in which a heat-curing type binder composition is used as a paint coating will be described. As shown in Figure 1, the binder composition 114 is applied onto the substrate 102. Methods for applying the binder composition include, for example, spray coating, roller coating, or brush coating. The binder composition should be applied to a thickness of 4 μm to 70 μm using the above application method.

[0120] Next, as shown in Figure 2, the binder composition 114 applied to the substrate 102 is subjected to heat treatment. For the heat treatment, refer to the description of the heat treatment for bringing the binder composition 114 to a semi-cured state. By performing the heat treatment, a semi-cured binder composition 114A is formed. The thickness of the semi-cured binder composition 114A is 3 μm or more and 50 μm or less.

[0121] Methods for applying the chlorhexidine solution 116 onto the semi-cured binder composition 114A include, for example, spray coating, roller coating, or brush coating. The chlorhexidine solution should be applied to a thickness of 1 μm to 120 μm using the above-described application method.

[0122] Next, the semi-cured binder composition 114A coated with chlorhexidine solution 116 is subjected to further heat treatment. For details on the heat treatment, please refer to the description of the heat treatment for curing and drying the binder composition 114A. By performing the heat treatment, a binder layer 104 can be formed. The thickness of the binder layer 104 is 3 μm to 50 μm, the thickness of the chlorhexidine layer 106 after drying is 0.5 μm to 60 μm, and the thickness of the mixed region 108 is 0.1 μm to 5 μm.

[0123] Next, we will describe the case where a room-temperature curing binder composition is used as a paint coating. As shown in Figure 1, the binder composition 114 is applied onto the substrate 102. The method for applying the binder composition 114 is the same as the method for applying a heat-curing binder composition. The binder composition 114 should be applied to a thickness of 5 μm to 90 μm using the application method described above.

[0124] Next, as shown in Figure 2, the binder composition 114 applied to the substrate 102 is subjected to a drying treatment. For the drying treatment, refer to the description of the drying treatment to bring the binder composition 114 to a semi-cured state. By performing the drying treatment, a semi-cured binder composition 114A is formed. The thickness of the semi-cured binder composition 114A is 3 μm or more and 50 μm or less.

[0125] Methods for applying the chlorhexidine solution 116 onto the semi-cured binder composition 114A include, for example, spray coating, roller coating, or brush coating. The chlorhexidine solution should be applied to a thickness of 1 μm to 120 μm using the above-described application method.

[0126] Next, the semi-cured binder composition 114A coated with chlorhexidine solution 116 is subjected to further heat treatment. For details on the heat treatment, please refer to the description of the heat treatment for curing and drying the binder composition 114A. By performing the heat treatment, a binder layer 104 can be formed. The thickness of the binder layer 104 is 3 μm to 50 μm, the thickness of the chlorhexidine layer 106 after drying is 0.5 μm to 60 μm, and the thickness of the mixed region 108 is 0.1 μm to 5 μm.

[0127] In this specification, "semi-cured dry state" is defined based on JIS K5600-1-1:1999 (General test methods for paints - Part 1: General rules - Section 1: General matters). Test specimens were prepared in accordance with the regulations, and the drying state of the test specimens was evaluated according to the following criteria (see item 4.3.5). [Touch dry] The state in which the fingertip does not get dirty when lightly touching the center of the painted surface with a fingertip. This is the state known as tack-free. If there is stickiness when lightly touched and then released, it has not reached touch dry. [Semi-cured dry] The state in which no scratches are left on the painted surface when the center of the painted surface is gently rubbed with a fingertip. [Cured dry] The state in which no indentations are left on the painted surface by firmly pinching the center of the painted surface with the thumb and index finger, no movement of the paint film is felt, and no scratches are left on the painted surface when the center of the painted surface is rapidly and repeatedly rubbed with a fingertip. Even if the painted surface is indented, if it recovers due to elasticity, it is not judged as being indented.

[0128] As explained above, even when the binder composition 114 is used as a paint coating, it is possible to apply the binder composition 114 and the chlorhexidine solution 116 to the substrate 102. If a room-temperature curing binder composition is used, it is possible to form the chlorhexidine layer 106 in the atmosphere, so the coating member 100 can be applied inexpensively on-site to large structures such as building materials, wall materials, and floor materials. Furthermore, since the chlorhexidine layer 106 is exposed on the surface of the coating member 100, an immediate effect of antibacterial, antifungal, or antiviral effects can be obtained. In addition, since the chlorhexidine free base contained in the chlorhexidine layer 106 has low solubility in water and disinfectant ethanol, its easy dissolution is suppressed. Therefore, the duration of the antibacterial, antifungal, or antiviral effect of the coating member 100 can be improved.

[0129] <13. Antifungal effect of coating material> The coating member 100 according to one embodiment of the present invention may have an antifungal effect. Specifically, it exhibits an antifungal effect against Candida fungi. The site of action of chlorhexidine is the cell membrane (lipid membrane) of fungi. Therefore, the coating member 100 according to one embodiment of the present invention will similarly exhibit an antifungal effect against fungi other than those exemplified above.

[0130] <14. Antiviral effect of coating material> The coating member 100 according to one embodiment of the present invention may have an antiviral effect. Specifically, it exhibits an antiviral effect against enveloped viruses and non-enveloped viruses.

[0131] As an example, let's explain the mechanism by which free chlorhexidine bases disrupt the viral envelope in aqueous solution. In aqueous solution, small amounts of dissolved free chlorhexidine bases can associate with viruses dispersed in the solution. Interaction occurs when the chemical structure and three-dimensional structure of chlorhexidine match those of proteins on the viral surface, including the spike protein. Consequently, large structures such as the six-membered ring of chlorhexidine can be inserted into the membrane surface, significantly disrupting the stability of the envelope's lipids. In this way, by acting on the envelope with chlorhexidine and altering it, the three-dimensional structure of the virus can be disrupted.

[0132] Viruses are prone to errors in their genetic information during proliferation and replication. Therefore, viruses are known to mutate rapidly, and mutant strains appear one after another. Such mutations often occur in spike proteins, affecting the effectiveness of vaccines. The coating material according to one embodiment of the present invention exhibits a virus-inactivating effect even against mutant strains of the virus.

[0133] <15. Antibacterial, Antifungal, and Antiviral Effects of Chlorhexidine Solution> The chlorhexidine solution 116 described in this embodiment has antibacterial, antifungal, or antiviral effects. Therefore, the chlorhexidine solution 116 may be applied to the substrate 102 without forming a binder layer 104. When applying the chlorhexidine solution 116 to the substrate 102 without forming a binder layer 104, the substrate 102 may be wood, woven fabric, nonwoven fabric, nonwoven protective clothing, or paper such as Japanese paper. After applying the binder composition 114 to the substrate 102, the solvent contained in the chlorhexidine solution 116 can be evaporated by performing the heat treatment or drying treatment described above. This allows the chlorhexidine layer 106 to be formed directly on the substrate 102. For the thickness of the chlorhexidine solution 116 immediately after application and the thickness of the chlorhexidine layer 106, please refer to the previous explanation.

[0134] Evaluation 1 [Structure of the coated member] This section describes the results of observing the surface and cross-section of a coated member manufactured according to one embodiment of the present invention.

[0135] First, the method for manufacturing the coating member 100 used here will be explained with reference to Figures 1 to 4. Here, a room-temperature curing binder composition was used.

[0136] As STEP 1 of the method for preparing a room-temperature curing binder composition, the main component of a two-component composition was prepared. First, 15.9% by weight of a silicone resin represented by general formula (1) (SILRES® MK silicone resin manufactured by Asahi Kasei Wacker Silicone Co., Ltd.) was added as polysiloxane, and 5.7% by weight of IPA was added and stirred. Stirring was carried out, for example, at 85°C using a tornado mixer (600 rpm) for 65 minutes.

[0137] In STEP 2, the composition prepared in STEP 1 was mixed with, for example, 5.9% by weight of polydimethylsiloxane represented by general formula (2) (polydimethyl silicate (PDMS) "EL0039G" manufactured by Gootech Co., Ltd. (distributor: Juke Co., Ltd.) as a polysiloxane), 67.5% by weight of silicone resin represented by general formula (3) (silicone resin SILRES® MSE100 manufactured by Asahi Kasei Wacker Silicone Co., Ltd.), and 1.5% by weight of fused silica. Furthermore, to promote room-temperature curing, 2.5% by weight of TEOS ("TEOS40WN" manufactured by Asahi Kasei Wacker Silicone Co., Ltd.) as a silicon-containing compound, and 1.0% by weight of titanium diisopropoxybis(ethyl acetate) ("Orgatics TC-750" manufactured by Matsumoto Fine Chemical Co., Ltd.) as an organometallic compound. The mixture obtained by mixing these was stirred. The mixture was stirred, for example, at 85°C using a tornado mixer (600 rpm) for 65 minutes. This prepared a two-component main component composition.

[0138] Immediately before applying the binder composition to the substrate, the binder composition according to Example 1 was prepared by adding 3.0% by weight of zirconium octylate (Nikka Octix® Zirconium, manufactured by Nippon Chemical Industrial Co., Ltd.) as a curing agent to 100% by weight of the main component of the two-component composition.

[0139] Next, 50.0% by weight of chlorhexidine-based white powder (Chlorhexidine BaseCHB) (CAS#55-56-1) manufactured by Liaoning Jiahe Shengshi (JS) Pharmaceutical Technology was added as chlorhexidine powder, and 50.0% by weight of texanol was added as a solvent. The mixture was stirred at 80°C in a tornado mixer (600 rpm) for 65 minutes to prepare a chlorhexidine solution with printable viscosity.

[0140] (Sample 1) The coating member 100 (Sample 1) according to Example 1 was formed as follows. First, the binder composition 114 according to Example 1 was applied to polyethylene terephthalate (PET) as a base material 102 by printing to a film thickness of 10 μm to 13 μm (calculated value), and dried at 60°C to 70°C for 15 to 20 minutes. This formed a semi-cured binder composition 114A with a film thickness of 7 μm to 10 μm. Next, the chlorhexidine solution 116 was applied to the semi-cured binder composition 114A by printing to a film thickness of 4 μm to 6 μm (calculated value), and dried at 120°C to 130°C for 15 to 20 minutes. A chlorhexidine layer 106 with a film thickness of 8 μm to 11 μm and a mixed region 108 of the binder layer 104 and the chlorhexidine layer 106 were formed.

[0141] The surface of sample 1, formed as described above, was observed using SEM. Figure 5 shows the surface SEM image of the coated material. The surface roughness of sample 1 was also measured in a 1 cm square area using a surface roughness measuring instrument (Surfcoder SE 4000). The surface roughness of sample 1 was 0.261 μm in Ra value (arithmetic mean roughness, JIS B0601:2013) and 1.736 μm in Rz value. From Figure 5 and the surface roughness measurement results, it was found that the surface of sample 1 is flat.

[0142] Next, in order to perform STEM observation of the cross-section of the coated material, a tungsten film was deposited on the surface of sample 1 as a conductive layer 150. Figure 6 is a cross-sectional STEM image of sample 1. Figure 7 is the result of EDX mapping analysis of carbon (C) in the cross-sectional STEM image. Figure 8 is the result of EDX mapping analysis of oxygen (O) in the cross-sectional STEM image. Figure 9 is the result of EDX mapping analysis of nitrogen (N) in the cross-sectional STEM image. Figure 10 is the result of EDX mapping analysis of chlorine (Cl) in the cross-sectional STEM image.

[0143] In the EDX mapping image shown in Figure 7, carbon (C) was not detected in any region. In the EDX mapping image shown in Figure 8, the region where oxygen (O) was detected corresponds to the binder layer 104 and the mixed region 108 formed above it. The bright region in the center of the EDX mapping image shown in Figure 8, when compared with the cross-sectional STEM image shown in Figure 6 and other EDX mapping images, is thought to be oxygen from the air that has entered the depressions of the chlorhexidine layer 106 or clumps of poorly dispersed silicone resin contained in the binder layer.

[0144] In the images obtained by EDX mapping analysis shown in Figures 9 and 10, the regions where neither nitrogen (N) nor chlorine (Cl) was detected correspond to the binder layer 104. Also in Figures 9 and 10, among the regions where nitrogen (N) and chlorine (Cl) were detected in the EDX mapping analysis images, the brighter areas correspond to the chlorhexidine layer 106. Furthermore, in Figures 9 and 10, among the regions where nitrogen (N) and chlorine (Cl) were detected in the EDX mapping analysis images, the mixed region 108 is brighter than the region corresponding to the binder layer 104 and darker than the region corresponding to the chlorhexidine layer 106.

[0145] The thickness of the chlorhexidine layer 106 can be measured using the EDX mapping analysis images in the cross-sectional STEM images shown in Figures 9 and 10. Furthermore, the thickness of the mixed region 108 can be measured using the EDX mapping analysis images in the cross-sectional STEM photographs shown in Figures 9 and 10.

[0146] The EDX mapping analysis results shown in Figures 7 to 10 revealed that the entire region is composed of inorganic materials. It was found that a chlorhexidine layer 106 is formed on top of the binder layer 104 to a thickness of 1 μm or more. It was found that a mixed region 108 exists between the binder layer 104 and the chlorhexidine layer 106 where the silicone resin and chlorhexidine are mixed together.

[0147] Evaluation 2 [Antibacterial effect of coating material] This section describes the results of antibacterial tests conducted on the coating material according to Example 1 (Sample 1) and the coating material according to Control Example 1 (Control Sample 1) in accordance with JIS Z2801 (ISO 22196).

[0148] (Sample 1) First, Sample 1 was prepared according to the same manufacturing method as the coating member described in Example 1.

[0149] (Control Sample 1) To confirm the antibacterial effect of chlorhexidine, a coated member without a chlorhexidine layer 106 was formed. First, the binder composition 114 described in Example 1 was prepared. Next, the coated member corresponding to Control Example 1 (Control Sample 1) was formed as follows. On polyethylene terephthalate (PET) as the base material 102, the binder composition 114 described in Example 1 was applied by print printing to a film thickness of 10 μm to 13 μm (calculated value), and a cured binder layer 104 was formed by drying at 120°C to 130°C for 15 to 20 minutes.

[0150] Next, an antibacterial test was performed on the coating member corresponding to Example 1 (Sample 1) and the coating member corresponding to Control Example 1 (Control Sample 1). The antibacterial test involved applying 1 × 10⁻¹⁶ to a 50 mm × 50 mm (thickness 0.1 mm) test piece (Sample 1 and Control Sample 1). 5 CFU / mL~1×10 8 A bacterial suspension at CFU / mL was dropped onto the specimen and covered with a 40 mm x 40 mm film. This specimen was incubated statically for 24 hours at 35 ± 1°C and a relative humidity of 90% or higher. After washing and collecting the test bacteria from the specimen, multiple 10-fold dilutions were performed using SCDLP, and each dilution was spread onto a Luria-Bertani agar plate placed in a petri dish. Static incubation was performed at 37°C for 16 hours, and the bacterial colonies that appeared were counted and measured in 1 cm increments. 2 The number of viable bacteria per unit was measured and calculated.

[0151] The antimicrobial activity value R was calculated according to formula (1). R = Ut - At .... (1) R: Antimicrobial activity value Ut: 1 cm after 10 minutes of the untreated test piece (control sample 1) 2Average value of the logarithmic number of viable bacteria per unit area At: 1 cm after 10 minutes of antibacterial treated test piece (sample 1) 2 The average value of the logarithm of the number of viable bacteria per unit area.

[0152] In addition, the bacteria used included methicillin-resistant Staphylococcus aureus N315, OM584, Mu50, methicillin-sensitive Staphylococcus aureus 209P, vancomycin-resistant Enterococcus faecalis ATCC29212, ATCC51299, NCTC12201, wild-type Pseudomonas aeruginosa PAO1, and Pseudomonas aeruginosa resistance gene quadruple knockout strain YM64.

[0153] Figure 11 is a bar graph summarizing the antibacterial test results of the coating material (sample 1) corresponding to Example 1. Figure 12 is a bar graph summarizing the antibacterial test results of the coating material (control sample 1) corresponding to Control Example 1.

[0154] As shown in Figure 11, the antibacterial activity value of sample 1 was at least 3.6, and generally around 6. An antibacterial activity value of 2.0 or higher (a mortality rate of 99% or more) indicates an antibacterial effect. Sample 1 was confirmed to have a high antibacterial effect not only against Pseudomonas aeruginosa wild strain PAO1 but also against all drug-resistant strains. In contrast, as shown in Figure 12, the control sample 1 had an antibacterial activity value of approximately 1.0. In other words, the antibacterial activity value of control sample 1 was less than 2.0, confirming that it had no antibacterial effect.

[0155] In this embodiment, it was confirmed that the coating material could achieve a high antibacterial effect against drug-resistant bacteria in a short time of 10 minutes.

[0156] (Sample 2 and Control Sample 2) A coating member (Sample 2) corresponding to Example 2 was prepared using Japanese paper instead of polyethylene terephthalate (PET) as the base material 102, and otherwise in the same manner as in Example 1. Similarly, in order to confirm the antibacterial effect of chlorhexidine, a coating member (Control Sample 2) corresponding to Control Example 2 was formed without a chlorhexidine layer.

[0157] (Sample 3 and Control Sample 3) A coating member (Sample 3) corresponding to Example 3 was prepared in the same manner as in Example 1, except that a nonwoven fabric was used as the base material 102 instead of polyethylene terephthalate (PET). Similarly, in order to confirm the antibacterial effect of chlorhexidine, a coating member (control sample 3) corresponding to control example 3 was formed without a chlorhexidine layer.

[0158] Antimicrobial tests were performed on sample 2 and control sample 2, and on sample 3 and control sample 3, in the same manner as in Example 1. Methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 were used as the bacteria.

[0159] In sample 2, the antibacterial activity value against both methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 was at least 7.50. In sample 3, the antibacterial activity values ​​against both methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 were at least 7.60 and 7.40, respectively. An antibacterial activity value of 2.0 or higher (a mortality rate of 99% or more) indicates an antibacterial effect. In contrast, control samples 2 and 3 had values ​​of approximately 0. In other words, the antibacterial activity values ​​were less than 2.0, confirming that neither control sample 2 nor control sample 3 had any antibacterial effect.

[0160] In this embodiment, the coating material was found to provide a high antibacterial effect against drug-resistant bacteria in a short time of 10 minutes when applied to various substrates.

[0161] (Sample 4 and Control Sample 4) A coating member corresponding to Example 4 (Sample 4) was prepared using oranexidine instead of chlorohexidine as the biguanide compound, and otherwise in the same manner as in Example 1. Similarly, in order to confirm the antibacterial effect of oranexidine, a coating member corresponding to Control Example 4 (Control Sample 4) was formed without an oranexidine layer.

[0162] Antimicrobial tests were performed on sample 4 and control sample 4 in the same manner as in Example 1. Methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 were used as the bacteria.

[0163] As shown in Figure 13, the antibacterial activity values ​​for sample 4 against methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 were at least 6.80 and 6.85, respectively. An antibacterial activity value of 2.0 or higher (a mortality rate of 99% or more) indicates an antibacterial effect. In contrast, the control sample 4 showed a value of almost 0. In other words, the antibacterial activity value of control sample 4 was less than 2.0, confirming that it had no antibacterial effect.

[0164] In this embodiment, it was confirmed that a high antibacterial effect against drug-resistant bacteria can be obtained in a short time of 10 minutes using a biguanide compound in the coating member.

[0165] (Sample 5 and Control Sample 5) As STEP 1 of the method for preparing a room-temperature curing binder composition, the main component of a two-component composition was prepared. First, 4.7% by weight of monomer-type ethyl silicate (Wacker® SILICATE TES 28) and 5.9% by weight of polydimethylsiloxane represented by general formula (2) (polydimethyl silicate (PDMS) "EL0039G" manufactured by Gootech Co., Ltd. (distributor: Juke Co., Ltd.)) were mixed as polysiloxane, and this mixture was stirred. Stirring was carried out, for example, at 46°C using a homomixer (6000 rpm) for 30 minutes.

[0166] In STEP 2, the mixture obtained by adding 0.2% by weight of water and 0.2% by weight of acetic acid to the composition prepared in STEP 1 was stirred. The stirring was performed, for example, at 46°C using a homomixer (6000 rpm) for 5 minutes. This prepared a two-component main component composition.

[0167] Immediately before applying the binder composition to the substrate, the binder composition according to Example 5 was prepared by adding 0.3% by weight of zirconium octylate (Nikka Octix® Zirconium, manufactured by Nippon Chemical Industrial Co., Ltd.) as a curing agent to 100% by weight of the main component of the two-component composition.

[0168] Next, 11.8% by weight of chlorhexidine-based white powder (Chlorhexidine BaseCHB) (CAS#55-56-1) manufactured by Liaoning Jiahe Shengshi (JS) Pharmaceutical Technology was added as chlorhexidine, to which 14.2% by weight of 1,2-propanediol, 3.5% by weight of 1,2,3-propanetriol and 59.5% by weight of ethyl alcohol were added as solvents. The mixture was stirred at 46°C with a homomixer (7000 rpm) for 40 minutes to prepare a chlorhexidine solution with printable viscosity.

[0169] On top of the semi-cured and dried binder composition 114A formed in the same manner as in Example 1, the chlorhexidine solution 116 according to Example 5 was applied by print printing to a film thickness of 4 μm to 6 μm (calculated value), and dried at 120°C to 130°C for 15 to 20 minutes. A chlorhexidine layer 106 with a film thickness of 8 μm to 11 μm and a mixed region 108 of the binder layer 104 and the chlorhexidine layer 106 were formed.

[0170] An antibacterial test was performed on sample 5 in the same manner as in Example 1. Methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 were used as bacteria. Similarly, to confirm the antibacterial effect of chlorhexidine, a coating member (control sample 5) according to control example 5, in which no chlorhexidine layer was formed, was created.

[0171] As shown in Figure 14, the antibacterial activity values ​​for sample 5 against methicillin-resistant Staphylococcus aureus N315 and wild-type Pseudomonas aeruginosa PAO1 were at least 6.70 and 6.85, respectively. An antibacterial activity value of 2.0 or higher (a mortality rate of 99% or more) indicates an antibacterial effect. In contrast, the control sample 4 showed a value of almost 0. In other words, the antibacterial activity value of control sample 5 was less than 2.0, confirming that it had no antibacterial effect.

[0172] In this embodiment, it was confirmed that a high antibacterial effect against drug-resistant bacteria can be obtained in a short time of 10 minutes using a biguanide compound in the coating member.

[0173] Evaluation 3 [Antiviral effect of coating material] Next, the results of ISO 21702 compliant tests conducted using various viruses on the coating material according to Example 1 (Sample 1) and the coating materials according to Comparative Examples 1 to 3 (Comparative Samples 1 to 3) will be described.

[0174] (Sample 1) First, Sample 1 was prepared according to the same manufacturing method as the coating member described in Example 1.

[0175] (Comparative Sample 1) Next, the method for preparing the coating member (Comparative Sample 1) corresponding to Comparative Example 1 will be described. As chlorhexidine, 50.0% by weight of chlorhexidine-based white powder (Chlorhexidine Base CHB) (CAS # 55-56-1) manufactured by Liaoning Jiahe Shengshi (JS) Pharmaceutical Technology, Inc. and 50.0% by weight of zirconium octoate (Nikka Octix® Zirconium) manufactured by Nippon Chemical Industrial Co., Ltd. were added, and the mixture was stirred at 80°C in a tornado mixer (600 rpm) for 65 minutes to dissolve the chlorhexidine powder. Subsequently, to achieve a viscosity suitable for screen printing, 10% by weight of polyester medium (PET100 Medium, manufactured by Jujo Chemical Co., Ltd.) was added as a thickening agent. Then, titanium diisopropoxybis(ethyl acetate) (OrganicsTC750, manufactured by Matsumoto Fine Chemical Co., Ltd.) was added as a curing agent, and the mixture was stirred at 80°C in a tornado mixer (600 rpm) for 65 minutes to prepare the main component of the thickened two-component composition.

[0176] Immediately before printing, titanium diisopropoxybis(ethyl acetate) ("Organics TC750" manufactured by Matsumoto Fine Chemical Co., Ltd.) was added as a curing agent to the main component of the two-component composition and stirred at room temperature to prepare the binder composition according to Comparative Example 1.

[0177] As a substrate, the binder composition according to Comparative Example 1 was applied to a 300-mesh polyester screen plate substrate by screen printing. The resulting coating was heated at 80°C for 30 minutes to evaporate the solvent contained in the binder composition and cure the binder composition to form a binder layer 104. The thickness of the binder layer 104 was 5 μm.

[0178] (Comparative Sample 2 and Comparative Sample 3) Next, the method for producing the coating members corresponding to Comparative Examples 2 and 3 (Comparative Sample 2 and Comparative Sample 3) will be described. First, as a substrate, 3 μm of alumina (Al) was deposited on a 5 cm x 5 cm SUS by the Aerosol Deposition Method (AD method). 2 O 3 A porous membrane (nanoporous membrane) of ) was formed to a size of 4 cm × 4 cm. Furthermore, a chlorhexidine solution prepared by dissolving chlorhexidine in ethyl acetate was used to inject 128 μg / cm³ into the porous membrane. 2 A chlorhexidine solution was applied and cured and dried. Comparative sample 2 and comparative sample 3 had the same composition.

[0179] An aerosol is a mixture of air or an inert gas and fine particles. The AD method is a method of directly forming a film containing fine particles on a substrate by spraying this aerosol from a nozzle towards the substrate and causing it to collide with the substrate. When forming a film using the AD method, it can be carried out at room temperature, and film formation can be performed without damaging the substrate 101 or impairing the properties of the raw material fine particles.

[0180] Antiviral tests were conducted on the coating members corresponding to Comparative Examples 1 to 3 and Example 1 (comparative samples 1 to 3 and sample 1) in accordance with ISO 21702. In the antiviral tests, 1 × 10⁻¹⁶ 6 PFU / mL~1×10 8 A virus suspension of influenza A virus containing PFU / mL was applied to the surface of the test specimen for 25 cm. 2 0.4 mL was added to each sample and covered with film. Antiviral testing was performed on each sample, along with control sample 1, under the same conditions.

[0181] Next, while preventing the test specimens from drying out, the coating members corresponding to Comparative Examples 1 and 2 (comparative sample 1 and comparative sample 2) were left standing at 25°C for 2 hours, and the coating members corresponding to Comparative Example 3 and Example 1 (comparative sample 3 and sample 1) were left standing at 25°C for 24 hours. Next, the surface of the test specimens was washed with 10 mL of SCDLP to recover any remaining viruses. Then, a 10-fold dilution series of the recovered solution was prepared using SCDLP.

[0182] Next, each dilution was spread onto a petri dish containing cultured MDCK cells (canine kidney cells), and the cells were subsequently cultured (this is called the plaque method).

[0183] Next, living cells were stained, and the areas that were not stained (indicating dead and detached cells) were counted. Finally, the viral infectivity titer was calculated from the count and dilution ratio.

[0184] The following formula (1) was used to calculate the viral infectivity titer: V = 10 × C × D ... (1) V: Viral infectivity titer (PFU / mL) C: Plaque count D: Dilution ratio of the wash solution

[0185] The antiviral activity value R was calculated according to the following formula (2): Antiviral activity value = log(Vb) - log(Vc) ... (2) Log(Vb): Common logarithm of the viral infectivity titer per 0.4g of control sample 1 after 2 hours or 24 hours Log(Vc): Common logarithm of the viral infectivity value per 0.4g of each sample after 2 hours or 24 hours

[0186] A sample was evaluated as having antiviral effects if its antiviral activity value R was 2.0 or higher.

[0187] Table 1 summarizes the results of the antiviral tests for the coating materials corresponding to Comparative Examples 1 to 3 (comparative samples 1 to 3) and the coating material corresponding to Example 1 (sample 1). Here, the inactivation rate refers to the percentage of virus inactivation calculated from the number of active viruses (PFU / mL) in the control sample and the test sample, respectively. The following formula (3) was used to calculate the inactivation rate.

[0188] ... (3)

[0189]

[0190] As shown in Table 1, the antiviral activity value R for comparative sample 1 was 0. An antiviral activity value of 2.0 or higher (a mortality rate of 99% or more) indicates an antiviral effect. In other words, no antiviral effect was observed in comparative sample 1. It is thought that the antiviral effect was inactivated because chlorhexidine no longer eluted onto the surface when mixed with the binder composition.

[0191] In contrast, sample 1 showed an antiviral activity value of 4.4, while comparative samples 2 and 3, which had chlorhexidine supported on a porous membrane, showed equivalent antiviral effects of 4.2 and 4.5, respectively. Therefore, it was confirmed that sample 1 exhibits a high antiviral effect.

[0192] An antiviral test against highly pathogenic avian influenza virus was performed on the coating member (sample 1) corresponding to Example 1, in accordance with ISO 21702. In the antiviral test, 1 × 10⁻⁶ 7 PFU / mL~5×10 7 A virus suspension of highly pathogenic avian influenza virus containing PFU / mL was applied to the surface of a test specimen for 25 cm. 2 0.4 mL was dropped onto each sample and covered with a film. Antiviral testing was performed on both sample 1 and control sample 1 under the same conditions.

[0193] Next, while preventing the test specimens from drying out, the coating materials corresponding to Sample 1 and Control Sample 1 (Sample 1 and Control Sample 1) were left standing at 25°C for 24 hours. Then, the surface of the test specimens was washed with 10 mL of SCDLP to recover any remaining viruses. Next, a 10-fold dilution series of the recovered solution was prepared using SCDLP.

[0194] According to formula (2), the antiviral activity value R (after 24 hours of standing) was calculated and showed a value of 3.7 or higher, confirming rapid viral inactivation.

[0195] In this embodiment, it was confirmed that a high antiviral effect against human and avian influenza viruses can be obtained within 24 hours using a biguanide compound in the coating member.

[0196] Although embodiments of the present invention have been described in detail above, it should be understood that modifications, alterations, and changes can be made without departing from the scope of the claims.

[0197] In the present invention, any effects or benefits other than those brought about by the embodiments described above, if they are clear from the description herein or easily predictable to a person skilled in the art, are naturally considered to be brought about by the present invention.

[0198] 100: Coating member, substrate; 102, 104: Binder layer; 106: Chlorhexidine layer; 108: Mixing region; 114, 114A: Binder composition; 116: Chlorhexidine solution; 150: Conductive layer

Claims

1. A coating member comprising a substrate, a binder layer provided on the substrate, and a biguanide compound layer containing a biguanide compound covering the binder layer, wherein the binder layer is in a cured and dried state of a binder composition containing polysiloxane, and further, a mixed region is formed between the binder layer and the biguanide compound layer in the thickness direction of the binder layer, where the polysiloxane and the biguanide compound are mixed.

2. The polysiloxane is represented by general formula (1): (wherein, R 1 and R 2 are each independently a hydrogen atom, a C 1 to C 3 alkyl group or a C 1 to C 3 alkoxy group. m1 and n1 are each independently an integer of 1 to 100, and m1+n1=10 to 100. Both terminals of the main chain may each independently be bonded to a hydrogen atom or a C 1 to C 3 alkyl group.); a silicone resin represented by general formula (2): (wherein, p is an integer of 250 to 400. Both terminals of the main chain may each independently be bonded to a hydrogen atom or a C 1 to C 3 alkyl group.); polydimethylsiloxane represented by general formula (3): (wherein, R 3 and R 4 are each independently a hydrogen atom, a C 1 to C 3 alkyl group or a C 1 to C 3 alkoxy group. m2 and n2 are each independently an integer of 1 to 10, and m2+n2=1 to 10. Both terminals of the main chain may each independently be bonded to a hydrogen atom or a C 1 to C 3 alkyl group.), or a combination of any thereof, the coating member according to claim 1.

3. The coating member according to claim 1 or 2, wherein the biguanide compound is chlorhexidine, oranexidine, or polyhexamethylene biguanide, and is in the form of a free base that does not contain an acid-derived anion.

4. The coating member according to any one of claims 1 to 3, wherein the substrate is selected from metal, ceramics, glass, plastic, concrete, stone, wood, woven fabric, nonwoven fabric, or Japanese paper.

5. A precursor for a coating member, comprising a substrate, a binder composition provided on the substrate, and a biguanide compound layer containing a biguanide compound covering the binder composition, wherein the binder layer is in a semi-cured and dried state of a binder composition containing polysiloxane.

6. A method for manufacturing a coated member, comprising: applying a binder composition containing a main component and a curing agent of a two-component composition containing at least polysiloxane to the surface of a substrate; heating or drying the binder composition to a semi-cured state; applying a biguanide compound solution containing a free base of a biguanide compound onto the semi-cured binder composition; and further heating or drying the binder composition to form a cured binder layer containing polysiloxane, a biguanide compound layer on the binder layer, and a mixed region between the binder layer and the biguanide compound layer in the thickness direction where the polysiloxane and the biguanide compound are mixed.

7. The solid content consists of the following components: (A) 40 to 95% by weight, preferably 60 to 90% by weight, more preferably 70 to 90% by weight of a polysiloxane compound, wherein the polysiloxane compound is a silicone resin represented by general formula (1); polydimethylsiloxane represented by general formula (2); or a silicone resin represented by general formula (3); or a combination thereof; (B) 1 to 20% by weight, preferably 1 to 10% by weight, more preferably 2 to 5% by weight of a silicon-containing compound, wherein the silicon-containing compound is selected from tetraalkyl orthosilicate (also known as "tetraalkoxysilane"; TEOS), silica, a mixture of TEOS and silica, vinyltrimethylsilane; (C) 0.5 to 10% by weight, preferably 1 to 10% by weight, more preferably 2 to 5% by weight of fused silica; and (D) 0.6% to 1.2% by weight of a curing agent or The method for producing the product according to claim 6, wherein (G) 0.5 to 10% by weight, preferably 0.5 to 5% by weight, more preferably 0.5 to 3% by weight, of an organometallic compound, the organometallic compound may include titanium diisopropoxybis(ethyl acetoacetate), tetrakis(2-ethylhexyl) or a combination thereof.

8. The manufacturing method according to claim 7, wherein the entire binder composition may further contain the following components: (E) water; an organic acid selected from formic acid, acetic acid, citric acid, malic acid, lactic acid, succinic acid, tartaric acid, and fumaric acid; or a catalyst selected from an inorganic acid selected from hydrochloric acid, nitric acid, and sulfuric acid.

9. The manufacturing method according to claim 7 or 8, wherein the binder composition may further contain the following component: (F) 1% to 25.0% by weight, preferably 3 to 20% by weight, more preferably 5 to 20% by weight, a solvent selected from methyl alcohol, ethyl alcohol, isopropyl alcohol (IPA), texanol (2,2,4-trimethylpentane-1,3-diol monoisobutyrate), plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, butanol, butylcarbitol acetate (BCA), in an amount of 1% to 25.0% by weight, preferably 3 to 20% by weight, more preferably 5 to 20% by weight.

10. The method for producing a product according to any one of claims 6 to 9, wherein the biguanide compound is chlorhexidine, oranexidine, or polyhexamethylene biguanide, and is in the form of a free base that does not contain an acid-derived anion.

11. The production method according to any one of claims 6 to 10, wherein the biguanide compound solution comprises a solvent selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, diisopropyl adipate, plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, or a combination thereof.

12. The manufacturing method according to any one of claims 6 to 11, wherein the content of the biguanide compound in the biguanide compound solution is 0.5% by weight or more and 65% by weight or less, preferably 5% by weight or more and 60% by weight or less, and more preferably 10% by weight or more and 50% by weight or less.

13. The manufacturing method according to any one of claims 6 to 12, wherein the main component of the two-component composition comprises a silicon-containing compound and fused silica.

14. The manufacturing method according to claim 13, wherein the main component of the two-component composition further comprises an organometallic compound.

15. A biguanide compound solution comprising a biguanide compound and a solvent selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol, texanol, diisopropyl adipate, plant-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, petroleum-derived 1,2-propanediol, 1,3-propanediol or 1,2,3-propanetriol, or combinations thereof, wherein the biguanide compound is chlorhexidine, oranexidine, or polyhexamethylene biguanide, and is in the form of a free base that does not contain anions derived from an acid.

16. General formula (1): (In the formula, R 1 and R 2 Each of these is independently a hydrogen atom, C 1 ~C 3 alkyl group or C 1 ~C 3 It is an alkoxy group. m1 and n1 are each an integer from 1 to 100, and m1 + n1 = 10 to 100. Both ends of the main chain are independently hydrogen atoms or C 1 ~C 3 A silicone resin represented by the following formula may have an alkyl group bonded to it: General formula (2): (In the formula, p is an integer between 250 and 400. Both ends of the main chain are independently hydrogen atoms or C 1 ~C 3 Polydimethylsiloxane represented by (which may have an alkyl group attached); and general formula (3): (In the formula, R 3 and R 4 These are, independently, hydrogen atoms and C 1 ~C 3 alkyl group or C 1 ~C 3 It is an alkoxy group. m2 and n2 are each an integer from 1 to 10, and m2 + n2 = 1 to 10. Both ends of the main chain are independently a hydrogen atom or C 1 ~C 3 The biguanide compound solution according to claim 15, further comprising a polysiloxane which is one selected from silicone resins represented by (which may have an alkyl group bonded to it, or any combination thereof).